Clinical trials
Atrophy clinical trials
Below are recruiting atrophy clinical trials, each written for real people, not researchers. We’re tracking 270 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Gilbert, ArizonaAges 60 years+ - NCT07392255RecruitingPhase 1/Phase 2
Testing CTx001 for geographic atrophy (GA) in AMD
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Carmel, IndianaAges 55 years+ - NCT06831214Recruiting
Bone growth with collagen membrane graft for jaw atrophy
This trial studies a new technique to help build up bone in the upper jaw (maxilla) that has become thin. It uses a special membrane and graft material to encourage bone growth, which may help people who need dental implants.
CairoAges 18–60 - NCT06821256Recruiting
Testing brain stimulation for multiple system atrophy
This trial tests if a gentle electrical current applied to the scalp can help people with a specific type of multiple system atrophy (the cerebellar variant) improve walking and other symptoms. The goal is to see if this non-invasive treatment is safe and effective.
Salerno, SaAges 40–90 - NCT06726746Recruiting
Laser treatment for vaginal dryness after menopause
This study tests if a fractional CO2 laser can safely improve vaginal atrophy symptoms like dryness, irritation, or pain during sex in postmenopausal women. It offers a non-hormonal option for those who haven't used hormone therapy or vaginal products recently.
CairoAges 45–65 - NCT07191327Recruiting
Testing brain stimulation for posterior cortical atrophy
This study tests a noninvasive brain stimulation technique called HD-tDCS to see if it can help people with posterior cortical atrophy (PCA), a condition that affects vision and spatial skills. You would receive personalized stimulation sessions, and the study aims to learn if this treatment improves symptoms.
Ann Arbor, MichiganAges 50 years+ - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT07230834RecruitingPhase 1
Testing an injection for advanced dry AMD with geographic atrophy
This trial tests whether a monthly injection of pozelimab into the eye can slow the growth of geographic atrophy (a late form of dry age-related macular degeneration). It may help people who have significant vision loss from this condition.
Lakewood, ColoradoAges 50 years+ - NCT07531719Recruiting
Risdiplam treatment study for type I and II spinal muscle atrophy
This study follows children with spinal muscular atrophy (SMA)—a genetic condition causing muscle weakness—who are being treated with a medicine called risdiplam. Researchers want to understand how well the treatment works and how it affects daily life in young patients.
CairoAges Up to 5 years - NCT07144137Recruiting
Observation study for geographic atrophy progression
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
Mountain View, CaliforniaAges 55 years+ - NCT07729982Recruiting
Study tracking vision changes in OPA1 optic atrophy
This study follows people with a genetic form of optic atrophy over time to understand how vision changes. It does not test a treatment but helps doctors learn more about the condition to improve care.
Munich, BavariaAges Any age - NCT06568237RecruitingPhase 2
Testing TEV-56286 for Multiple System Atrophy
This trial tests a new drug called TEV-56286 for people with Multiple System Atrophy (MSA), a rare brain disorder. It aims to see if the drug can help control symptoms and slow the disease.
La Jolla, CaliforniaAges 30–75 - NCT03217578Recruiting
Newborn screening for spinal muscular atrophy in Taiwan
This trial offers testing for spinal muscular atrophy (SMA) to newborns. It aims to identify SMA early so families and doctors can act sooner if results suggest the condition.
Kaohsiung CityAges birth–2 weeks - NCT03761446Recruiting
Testing how diabetes affects muscle loss after bed rest
This study looks at how pre-diabetes or type 2 diabetes may change skeletal muscle loss and recovery in older adults after a period of bed rest. It may help researchers understand why recovery can be slower and how to better protect muscle in people as they age.
Orlando, FloridaAges 60–80 - NCT03811808Recruiting
Multidisciplinary clinic visits for multiple system atrophy care
This study involves people with possible or probable multiple system atrophy (MSA) joining a specialized clinic team and attending visits every 4 months. It’s meant to improve care planning and support by bringing different specialists together.
Dallas, TexasAges 18 years+ - NCT04165486RecruitingPhase 1
Test drug safety in adults with multiple system atrophy
This Phase 1 study checks how safe a drug called ION464 is, how the body handles it, and how much of the drug reaches the bloodstream in adults with multiple system atrophy (MSA). It may help researchers find a dosing approach for future treatments for MSA.
InnsbruckAges 40–70 - NCT04174157Recruiting
Spinal muscular atrophy patient registry for OAV-101
This is a registry that collects information from people with spinal muscular atrophy (SMA) who have been treated with OAV-101. It helps researchers understand how patients do over time after this treatment.
Phoenix, ArizonaAges Any age - NCT04177134Recruiting
French patient registry for spinal muscular atrophy (SMA 5q)
This trial is a patient registry that collects health information from people with spinal muscular atrophy (SMA) caused by changes in the 5q area. It helps researchers understand real-world care and outcomes for these patients across French hospitals.
GarchesAges birth+ - NCT04250493Recruiting
Testing insulin resistance in multiple system atrophy
This study looks at how the body handles blood sugar (insulin resistance) in people with multiple system atrophy (MSA). Results may help doctors understand the disease better and explore new ways to monitor or treat it.
BordeauxAges 30 years+ - NCT04339764RecruitingPhase 1/Phase 2
iPS cell eye transplant for dry macular degeneration
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
Baltimore, MarylandAges 55–95 - NCT07160179RecruitingPhase 1/Phase 2
Study of an eye injection for geographic atrophy
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
Carmel, IndianaAges 50 years+ - NCT04944940Recruiting
Study tests blood, scans, and genes in SBMA and healthy men
This study looks for early “biomarkers” (measurable signs) in the body using blood tests, imaging scans, and sometimes other procedures in men with genetically confirmed spinal and bulbar muscular atrophy (SBMA). The results may help future drug studies by showing better ways to track disease changes over time.
Bethesda, MarylandAges 18–120 - NCT05121012Recruiting
PET brain scan study for synaptic loss in MSA or PSP
This study uses brain scans (PET, and possibly spinal fluid) to measure changes linked to “synaptic loss” in people with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). It may help researchers understand disease changes and how they relate to symptoms, which could guide future treatments.
ExeterAges 45–80 - NCT05211986RecruitingPhase 1/Phase 2
Test injection safety for knee osteoarthritis muscle weakness
This Phase 1/2 trial studies whether an injection called IMM01-STEM is safe and well-tolerated for people with knee osteoarthritis who also have muscle weakness. It also looks at whether the treatment could help in this group, while carefully monitoring side effects.
Irvine, CaliforniaAges 50–75
Hear when a new Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for atrophy?
- Yes. Clin2 currently lists 270 recruiting atrophy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atrophy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atrophy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.